Finnish technology facilitates better health in Europe

Aiforia Technologies is to deliver its artificial intelligence-powered diagnostics solutions to Assistance Publique-Hôpitaux de Paris (AP-HP). The solutions will initially be utilised to analyse tissue samples taken from prostate cancer patients, marking the first introduction of algorithms to the workflow of the hospital, according to Catherine Guettier, director of pathological anatomy at AP-HP.

Becoming an early adopter of artificial intelligence, she added, is a natural step for the hospital given its involvement in piloting digital pathology solutions in France since 2018.

For Aiforia, the partnership is of tremendous strategic importance as it offers “exciting opportunities” for broader collaboration, summed up CEO Jukka Tapaninen.

“We’re honoured to have another world-leading hospital choose us as their partner,” he commented.

CurifyLabs, meanwhile, reported that it has joined forced with APL, one of the leading manufacturers of extemporaneous medications in Sweden. The objective of the partnership is to better the administration of medications to children and severely ill patients with 3D printing, an approach that can enable more personalised dosages and dosage forms and high-precision dosing to reduce side effects.

APL, for instance, has used a manufacturing method that produces a minimum of 100 capsules per batch. With 3D printing, it is possible to enhance dose precision while reducing waste and the risk of repetitive strain injuries and toxic exposures for staff.

“3D printing is an exciting technology that is well suited to extemporaneous manufacturing. It will give us additional opportunities to fulfil our public policy assignment,” said Erik Haeffler, CEO of APL.

With the Swedish company taking delivery of its first printers in September, it expects to launch fully compliant and validated 3D-printed medicines in Sweden by 2025.